ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s inhaled lipid nanoparticle (LNP) platform is the first to enable highly targeted delivery of genetic medicines to specific cells in the lungs. This platform's unique properties enable packaging and delivery of a wide range of genetic medicines through multiple routes of administration.
| Website | https://recodetx.com/ |
| Revenue | $14.8 million |
| Employees | 51 (40 on RocketReach) |
| Founded | 2015 |
| Phone | +1 469-306-1618 |
| Technologies |
JavaScript
,
HTML
,
PHP
+18 more
(view full list)
|
| Industry | Biotechnology Research, Drug Delivery, Pharmaceuticals |
| Keywords | Mrna Therapeutics, Gene Editing, Gene Therapy, Lipid Nanoparticles, Targeted Drug Delivery, Next Generation Therapeutics, Drug Delivery, Therapeutic Delivery, Clinical Stage, Biotechnology, Pharmaceutical, Precision Medicine, Novel Therapeutics, Advanced Therapeutics |
| Competitors | Vertex Pharmaceuticals, Moderna Therapeutics, Alnylam Pharmaceuticals, BioMarin Pharmaceutical Inc., Akcea Therapeutics, Novartis, Pfizer, Regeneron, Amgen, Gilead Sciences +40 more (view full list) |
Looking for a particular ReCode Therapeutics employee's phone or email?
The ReCode Therapeutics annual revenue was $14.8 million in 2026.
Heather Clark is the CEO of ReCode Therapeutics.
40 people are employed at ReCode Therapeutics.
ReCode Therapeutics is based in Mountain View, California.